Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The objective of the trial is to provide regorafenib to subjects diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy. Selected additional safety information on regorafenib will be collected and progression-free survival (PFS) will be estimated.
Epistemonikos ID: 4b524a004aa38cb505373c4d5576837b4ddbff87
First added on: May 11, 2024